Background
Background
Blue dye with or without isotope has been widely used to identify the sentinel lymph node(s) in breast cancer. Patent blue V is used in the UK while its isomer isosulfan blue is used in the US. The allergic potential of isosulfan blue is well documented (1.4% adverse reactions) but that of patent blue V is less clearly defined.
Methods
In this paper we review the adverse reactions of patent blue V in 7,917 patients participating in the NEW START training programme and the ALMANAC trial. All patients underwent sentinel lymph node biopsy for breast carcinoma using patent blue V in combination with 99m Tc-albumin colloid.
Results
In total, 72 of 7,917 (0.9 %) patients experienced adverse reactions : non-allergic reactions were observed in 4 (0.05%) patients, 23 (0.3%) patients had minor grade I allergic skin reactions (urticaria, blue hives, pruritis, or generalised rash) and 16 (0.2%) had grade II reactions (transient hypotension/ bronchospasm /laryngospasm).
Severe Grade III reactions (severe hypotension requiring vasopressor support and/or and/or change / abandoning of planned procedure and/or HDU/ITU admission) were noted in 5 (0.06%). The type of adverse reaction was not specified in 24 (0.3%) patients. No mortality was recorded.
Conclusion
The allergic potential of patent blue V dye compares favourably with isosulfan blue however both surgeon and anaesthetist need to be alert to the risk of allergic reactions.
Introduction
Patent blue V dye has been used since the 1960's in lymphangiography. It is a 2,5 disulfonated calcium-chelated dimer of the triphenylmethane family (CAS number 3536-49-0). 1 Outside medicine it is used in textiles and as a food colourant (E 131) and potentially exposes the general population to the risk of allergic sensitisation. 2 With its use in sentinel lymph node biopsy there is a renewed interest in its medical role. We reviewed our experience of its allergic potential in the large number of patients in the NEW START training programme and the ALMANAC trial. In addition, we searched the ADROITE database of the Committee of Safety of Medicines and the pharmacovigilance files of the manufacturer (Laboratoire Guerbet, Aulnay-Sous-Bois, France) and compared the rate of adverse effects of patent blue V with other dyes, namely isosulfan and methylene blue.
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Patients and Methods
Before implementing sentinel lymph node biopsy (SLNB) for axillary nodal staging we investigated the procedure in a multicentre, randomised study (ALMANAC randomised controlled trial) 3 preceded by a validation phase. We have now rolled out a UK -wide sentinel lymph node biopsy training programme (NEW START) in the UK to train breast teams and at the same time ensure patient safety.
Blue dye injection technique
In the ALMANAC validation phase and the ALMANAC randomised trial 2 ml of 2.5% aqueous solution of patent blue V diluted to 5 ml with normal saline was injected around the tumour. In the NEW START sentinel lymph node training programme undiluted 2 ml of 2.5 % patent blue V dye or 2 ml of 2.5 % aqueous solution of patent blue V diluted to 5 ml with normal saline was injected subdermally at the areola-skin margin of the index quadrant.
Adverse reactions
Side-effects after injection of patent blue V dye injection were recorded prospectively.
The participating surgeons described the specific reaction in a free-text box. Drug treatment of the reaction (histamine antagonist, steroids or vasopressor use), admission to intensive care unit or changes of procedure were recorded. The classification of blue dye allergic reactions described by Montgomery et al. 4 
Isosulfan blue
Several American studies have addressed the issue of allergic reactions following injection of isosulfan, an isomer of patent blue V, for sentinel lymph node biopsy in breast and melanoma patients ( predisposition. 6 Pre-operative antiallergic medication does not prevent anaphylactic reactions but can reduce severity. 10 
Omitting patent blue V increases the false-negative rate
In an effort to minimise blue dye morbidity some centres are now performing isotope only localisation. We have some concerns with regards to this: in the ALMANAC validation phase in 10% of patients the sentinel lymph node stained with blue dye, but did not take up 99m Tc-albumin colloid. More importantly, in approximately 4% patients, the sentinel node that was involved with metastatic disease was identified by blue dye alone. 11 An attractive option is to use blue dye selectively in the subgroup of patients in whom a hot node is not demonstrated on the lymphoscintiscan or cannot be detected with a gamma-probe. However, there is no published data on how this approach will influence the false-negative rate. NEW START dataset analyses will be able to answer this question, however till this is done all teams should use a combined technique (isotope and blue dye) for sentinel node localisation.
Methylene blue
Methylene blue dye due to its lower cost, lower allergic potential and lesser interference with pulse oximetry 12, 13 has been used as an alternative. Sentinel lymph node detection rates with methylene blue are similar to isosulfan blue [14] [15] [16] [17] [18] despite theoretical concerns about its poor lymphatic uptake due to its lack of sulfonic acid groups essential for binding to plasma proteins and absorption into lymphatics 19 .
However, it is associated with fat necrosis [20] [21] [22] and capsular contraction after implant surgery. 23 While its allergic potential is less as reflected in fewer reports in the published literature and to the Committee of Safety of Medicines it is by no means non-existent. 24, 25 M A N U S C R I P T
Anaesthesia related anaphylaxis
Anaesthesia related anaphylaxis has been estimated at between 1 in 10,000 -20,000. 26 Neuromuscular blocking drugs are the commonest cause of anaesthesia related reactions. Other causes are latex hypersensitivity, antibiotics, local anaesthetics, anaesthetic induction agents, antiseptics, opioids, NSAIDs and colloids. It can be difficult to recognize the causative factor in any allergic reaction in patients undergoing blue dye guided sentinel node biopsy during general anaesthesia.
However, the presence of blue hives is diagnostic of reaction to the blue dye.
Practice guidelines
We recommend that allergic risk should be documented and discussed with patients undergoing sentinel lymph node biopsy when taking consent. Patent blue V should be avoided in patients with an allergy history to foods containing food colorant E 131 or hyperallergic patients carrying an adrenaline-containing syringe for selfadministration (epipen®). However, omitting blue dye may adversely affect the failed localisation and false-negative rates.
The surgeon should verbally alert the anaesthetist when patent blue V dye is administered. Since the use of patent blue V dye is on a named basis only and a licence is unlikely to be issued in future, we encourage reporting of adverse effects of patent blue V dye to the Committee of Safety of Medicines with the Yellow Card System in the UK.
Conclusion
The allergic potential of patent blue V dye compares favourably with isosulfan blue.
Severe anaphylaxis is rare. However, surgical and anaesthetic teams need to be alert to the risk of allergic reactions. Table 3 . Allergic reactions to isosulfan blue compared to patent blue V dye
